Online Registration is Open!
Register by Tuesday, May 3 to Avoid the $100 Onsite Fee.
Printed from the IBC Life Sciences Web site on May 3, 2016 2:18 PM ET.
Page location: http://www.ibclifesciences.com/TIDES/testimonials.xml
May 09-12, 2016
Long Beach Convention & Entertainment Center
Long Beach, CA
"The entire field of peptides and oligonucleotides is relatively new compared to small molecules, making it difficult to get all of today's important information on the web. If you want to stay on the forefront in this field, TIDES is the conference you need to attend." - Bo Ying, Senior Scientist, Onkaido Therapeutics
"This is my 5th time attending TIDES. It is a great place to meet people and it is a scientifically stimulating meeting because a lot of innovation is happening in the field." - Toru Seo, Head of External R&D, Pfizer
"TIDES always manages to be interesting for industry and academia alike." - Roland Brock, Radboud University Medical Centre
"TIDES is a great opportunity to network and build relationships with others in the field and to learn about advances in the areas of oligonucleotide research, manufacturing, analytical, and regulatory affairs." - Edward Huber, Ph.D., Director, QC and Analytical Development, Avecia
"The peptide field is growing and the latest work is being reported at TIDES. If you work in the peptide field, then this is the show you need to attend. TIDES is recognized as a strong show in both Europe and US so you get a good global perspective of what's going on." - Mike Collins, President, CEM Corporation
"TIDES is an excellent opportunity to connect with the Oligo Industry, staying abreast of the latest developments while formulating strategies for the future." - Giuseppe Whelan, Project Leader, GlaxoSmithKline
"TIDES covered a wide range of topics and provided me with a great learning experience. I would recommend anyone to attend, regardless of their experience in the field." - Kelli Jette, Research Associate, Ra Pharmaceuticals Inc.
"The TIDES conference is a key venue to learn about early to late stage advances for all types of peptides and oligonucleotides therapeutics, and to learn from multiple disciplines across research and discovery, manufacturing, regulatory and clinical. The snapshot provided by TIDES is an efficient way to keep up on the field and meet a full spectrum of professionals that are making it happen." - Bob D. Brown, Ph.D., Dicerna Pharmaceuticals
"One of the great things about TIDES, in addition to the excellent program content, is the large exhibit hall which enables me to meet with many of the most relevant suppliers with just one trip." - Christoph Rosenbohm, Ph.D., Roche Innovation Center Copenhagen, Denmark
"TIDES represent the unique opportunity to meet hundreds of high level scientists and professionals in the peptide R&D and manufacturing community." - Joel Richard, Ph.D., Vice President, Ipsen, France
"The premier event to obtain an overview on hot topics in oligos and peptides and to network with opinion leaders." - Alex Fässler, Bachem AG, Switzerland
"Having the FDA and EMEA regulators walking around and talking to them [at TIDES] was great!" - Vidhya Gopalakrishnan, Senior VP of Pharmaceutical Development, Quark Pharmaceuticals
"The workshop was fabulous! I come from a small molecule background so the workshop really helped provide an overview of today's issues." - Dora Visky, Senior Research Scientist, Celgene Corporation
"We started attending TIDES five years ago on the recommendation of an oligo therapeutics client. We find that this venue offers unique access to 'C' level scientists from around the globe and the lectures are…first-rate" - Tom Falzareno, Tandem Labs
"Good conference" - Lloyd Tillman, Ionis Pharmaceuticals, Inc.
"An ideal setting to track progress from discovery through clinical development of peptide therapeutics and related strategies and approaches." - Craig Murphy, Ph.D., Head of Discovery Research, Protagonist Therapeutics, Australia
"I love to come to TIDES. The lectures and posters are very informative and the discussions are brain stimulating." - Meena Meena, Senior Director, WaVe Life Sciences
"TIDES is the premier venue to network with the experts in peptide and oligonucleotide development and to be on the pulse of current status and future trends in Biotech and Pharma." - Alex Fӓssler, Ph.D., COO Europe, Bachem AG, Switzerland
"Very interesting presentations from industry and academia make TIDES an excellent opportunity to know the hot-topics in peptide therapeutics. The dynamic, friendly atmosphere creates good networking opportunities." - Jose De Chastonay, Ph.D., MBA, Chief Marketing Officer, Bachem Group
"The TIDES conferences continue to attract participation from top caliber scientists developing the next generation of oligo/peptide therapeutics as well top notch tech ops, quality, clinical and regulatory personnel and companies to help convert the early stage products to real drugs. Good balance of participation on these skill sets, and a great venue to network and to keep abreast of current thinking in the field." - Jayant Aphale, Ph.D., MBA, RAC, Senior Vice President, Technical Operations, Sarepta Therapeutics
"The TIDES series of conferences is an indispensable catalyst for the industry to bring people together to share knowledge and address topics of common interest and ensure that we can help our business and the industry to grow and flourish. I meet clients and customers and educate myself enormously on projects that are running, products that are sold, huge potential for therapies to treat human diseases like cancer. I think we will be part of the breakthrough in taking human medicine that step further in treating complicated and difficult diseases that we have not been able to cure. I'm sure we are in the right therapeutic ingredient class that will play a great role in the future together with oligonucleotides. That's why I work in the peptide field. I like the combination of events…peptides and oligonucleotides: two nuclear generators of therapeutics for the future of diseases that have plagued mankind for our history. It's a special, special event. I always enjoy myself and find it incredibly enriching." - Lester Mills, Ph.D., MBA, Head of M&A, BASF
"For me, the TIDES meeting covers everything new between Adenosine to Z-form helix." - Steven F. Dowdy, Ph.D., Professor, Cellular and Molecular Medicine, UCSD School of Medicine
"I was pleasantly surprised to meet key players in the field of peptide research and learn about industrial implementations" - Ephraim Brener, Healor, Inc.
"Right balance between basic research and commercial applications" - Peter Timmerman, Pepscan Therapeutics
"The fact that small peptides usually lack a well-defined tertiary structure often makes them aggregation-prone, and simultaneously their small size presents problems for many common analytical techniques, so it can be a 'perfect storm' situation." - John Philo, Ph.D., Vice President, Alliance Protein Laboratories, Inc.
"This is a single conference connecting the latest developments on peptide and oligonucleotide innovation." - Farooq Z. Qureshi, Ph.D., Senior Principal Scientist, Research Leader, Pharmaceutical and Analytical R&D, Hoffmann-La Roche Inc.
"TIDES is an excellent opportunity to gain knowledge into the vastly expanding area of peptides and oligonucletides. Furthermore, it gives attendees an invaluable chance for networking and building relationships with other experts in the field." -Barry P. O'Connor, Ph.D., Research Scientist, R&D, Sekisui Medical Co., LTD., Japan
"At the TIDES annual conference, you have an opportunity to build potential partnerships and relationships that will help you both personally and professionally." - William Turner, Vice President, Regulatory Affairs and Corporate Quality Systems, Dynavax Technologies
"I've looked over the entire agenda and the TIDES 2012 seems like it will be one of the best, if not THE best, meeting I'll attend in 2012." - Richard A. Montagna, Ph.D., Senior Vice President for Corporate Business Development & Scientific Affairs, Rheonix, Inc.
"TIDES is a terrific venue to connect with colleagues in the peptide community, see new advances made in the development of peptides, and to discuss commonly encountered hurdles and the potential solutions to overcome them." - Angelika Fretzen, Ph.D., Ironwood Pharmaceuticals
"The TIDES conference is the pre-eminent event to present and discuss the resurgence of synthetic biologics." - Ian Lewis, Ph.D., Novartis Institutes of Biomedical Research, Switzerland
"Learn the valuable lesson in 30 minutes that took us 20 years to understand: how peptide aggregation-much more ubiquitous than once realized-can damage your clinical trials and, once solved, can enable success." - Candace B. Pert, Ph.D., RAPID Laboratories, Inc.
"Excellent oligonucleotide chemistry, discovery and optimization" - Steve Shrewsbury, AVI Biopharma
"The new format of a separate stream on Oligonucleotide Therapeutics Discovery has enhanced the value of this conference even further " - Michael Gait, Medical Research Council, United Kingdom
"TIDES is an excellent meeting to catch up on the latest efforts in industry on peptide therapeutics and technologies" - Suresh M. Pitram, Senior Research Investigator, Integrated Diagnostics
"Definitely the best meeting in the US for companies developing peptide therapeutics; not to be missed" - Rodney Lax, Ph.D., Senior Director, PolyPeptide Group
"I have never heard so many good lectures in so little time. Excellent program! Would go again next year." - Peter Timmerman, Chief Technology Officer, Pepscan Therapeutics
"TIDES 2011 was a very productive conference. I had lots of good meetings, with many types of companies. The marriage of the conferences on discovery and manufacturing will make this event a must be for people interested in the TIDES, particularly the oligonucleoTIDES field." - Sven Klussmann, Ph.D., Chief Scientific Officer, NOXXON Pharma AG, Germany
"The TIDES 2011 Conference was a very well organised event. I enjoyed the conference and found it a very good networking platform with vendors and other attendees from various pharmaceutical companies. I shared my latest data in a poster presentation which sparked off some interesting conversations, and I will be applying my learning's from the conference in my day to day investigations." - Nainesh Patel, Senior Scientist, GlaxoSmithKline, UK